These trials, which included SAFE [63], ALBIOS [66], and EARSS [65], collectively indicated a trend towards reduced mortality in sepsis patients receiving albumin with relative risks closely aligning from 0.87–0.94. The gene discussed is ALB; the disease is Sepsis.